Published in Clin Exp Immunol on August 01, 1990
Enterocolitis and colon cancer in interleukin-10-deficient mice are associated with aberrant cytokine production and CD4(+) TH1-like responses. J Clin Invest (1996) 7.97
Enhanced secretion of tumour necrosis factor-alpha, IL-6, and IL-1 beta by isolated lamina propria mononuclear cells from patients with ulcerative colitis and Crohn's disease. Clin Exp Immunol (1993) 4.68
Activation of nuclear factor kappa B inflammatory bowel disease. Gut (1998) 4.14
Location of tumour necrosis factor alpha by immunohistochemistry in chronic inflammatory bowel disease. Gut (1993) 3.25
Interleukin-2- and interferon-gamma-secreting T cells in normal and diseased human intestinal mucosa. Immunology (1993) 3.20
Serum concentrations of tumour necrosis factor alpha in childhood chronic inflammatory bowel disease. Gut (1991) 2.98
Intestinal barrier function: molecular regulation and disease pathogenesis. J Allergy Clin Immunol (2009) 2.63
Induction of NGAL synthesis in epithelial cells of human colorectal neoplasia and inflammatory bowel diseases. Gut (1996) 2.63
Significance of systemic endotoxaemia in inflammatory bowel disease. Gut (1995) 2.21
Expression of interleukin-8 gene in inflammatory bowel disease is related to the histological grade of active inflammation. Am J Pathol (1994) 2.04
Interferon-gamma (IFN-gamma)- and tumour necrosis factor (TNF)-induced nitric oxide as toxic effector molecule in chronic dextran sulphate sodium (DSS)-induced colitis in mice. Clin Exp Immunol (1999) 1.97
Pneumocystis jiroveci (carinii) pneumonia after infliximab therapy: a review of 84 cases. Dig Dis Sci (2007) 1.96
Infliximab in moderately severe glucocorticoid resistant ulcerative colitis: a randomised controlled trial. Gut (2003) 1.95
LRRK2 is involved in the IFN-gamma response and host response to pathogens. J Immunol (2010) 1.85
Downregulation of epithelial apoptosis and barrier repair in active Crohn's disease by tumour necrosis factor alpha antibody treatment. Gut (2004) 1.82
Claudin-1 and claudin-2 expression is elevated in inflammatory bowel disease and may contribute to early neoplastic transformation. Lab Invest (2008) 1.64
Nonlymphocyte-derived tumor necrosis factor is required for induction of colitis in recombination activating gene (RAG)2(-/-) mice upon transfer of CD4(+)CD45RB(hi) T cells. J Exp Med (1999) 1.46
Chemokine receptor CCR7 regulates the intestinal TH1/TH17/Treg balance during Crohn's-like murine ileitis. J Leukoc Biol (2015) 1.46
Tumour necrosis factor alpha converting enzyme (TACE) activity in the colonic mucosa of patients with inflammatory bowel disease. Gut (2002) 1.41
Activation of signal transducer and activator of transcription (STAT) 1 in human chronic inflammatory bowel disease. Gut (2002) 1.40
Adhesion molecules in inflammatory bowel disease. Gut (1995) 1.36
Cellular localization of tumor necrosis factor (TNF)-alpha transcripts in normal bowel and in necrotizing enterocolitis. TNF gene expression by Paneth cells, intestinal eosinophils, and macrophages. Am J Pathol (1993) 1.30
In situ expression of interleukin-10 in noninflamed human gut and in inflammatory bowel disease. Am J Pathol (1998) 1.28
The role of infection in the aetiology of inflammatory bowel disease. J Gastroenterol (2010) 1.26
Synergistic effects of interferon gamma and tumour necrosis factor alpha on T84 cell function. Gut (1999) 1.26
Detection of interferon gamma mRNA in the mucosa of patients with coeliac disease by in situ hybridisation. Gut (1994) 1.24
Cytokine mRNA expression in the mucosa of treated coeliac patients after wheat peptide challenge. Gut (1995) 1.18
Thalidomide reduces tumour necrosis factor alpha and interleukin 12 production in patients with chronic active Crohn's disease. Gut (2002) 1.17
Imbalance between interleukin-1 agonists and antagonists: relationship to severity of inflammatory bowel disease. Clin Exp Immunol (2004) 1.14
The ICE inhibitor pralnacasan prevents DSS-induced colitis in C57BL/6 mice and suppresses IP-10 mRNA but not TNF-alpha mRNA expression. Dig Dis Sci (2007) 1.12
The role of up-regulated serine proteases and matrix metalloproteinases in the pathogenesis of a murine model of colitis. Am J Pathol (2000) 1.12
Inflammatory pathways of importance for management of inflammatory bowel disease. World J Gastroenterol (2014) 1.09
Renal tubular dysfunction in patients with inflammatory bowel disease treated with aminosalicylate. Gut (1997) 1.08
Tumour necrosis factor alpha changes porcine intestinal ion transport through a paracrine mechanism involving prostaglandins. Gut (1994) 1.07
Tumor necrosis factor-alpha and apoptosis signal-regulating kinase 1 control reactive oxygen species release, mitochondrial autophagy, and c-Jun N-terminal kinase/p38 phosphorylation during necrotizing enterocolitis. Oxid Med Cell Longev (2010) 1.03
Anti-tumour necrosis factor alpha therapy for ankylosing spondylitis: international experience. Ann Rheum Dis (2002) 1.02
Increase in the tight junction protein claudin-1 in intestinal inflammation. Dig Dis Sci (2011) 1.01
Immunohistochemical analysis of mucosal gamma-interferon production in coeliac disease. Gut (1992) 1.01
Inhibition of leucocyte adhesion molecule upregulation by tumor necrosis factor alpha: a novel mechanism of action of sulphasalazine. Gut (1993) 1.01
A pro-resolution mediator, prostaglandin D(2), is specifically up-regulated in individuals in long-term remission from ulcerative colitis. Proc Natl Acad Sci U S A (2010) 1.01
Treatment with tumour necrosis factor inhibitor oxpentifylline does not improve corticosteroid dependent chronic active Crohn's disease. Gut (1997) 1.00
Increased expression of IL-16 in inflammatory bowel disease. Gut (2001) 1.00
Intestinal epithelial cells in inflammatory bowel diseases. World J Gastroenterol (2010) 0.97
A synergistic relationship between TNF-alpha, IL-1 beta, and TGF-beta 1 on IL-6 secretion by the IEC-6 intestinal epithelial cell line. Immunology (1995) 0.95
The proportion of Th1 cells, which prevail in gut mucosa, is decreased in inflammatory bowel syndrome. Clin Exp Immunol (2001) 0.93
JAM-related proteins in mucosal homeostasis and inflammation. Semin Immunopathol (2014) 0.93
Local and systemic liberation of proinflammatory cytokines in ulcerative colitis. Dig Dis Sci (1999) 0.92
The role of protein kinase CK2 in intestinal epithelial cell inflammatory signaling. Int J Colorectal Dis (2006) 0.92
Giardia induces proliferation and interferon gamma production by intestinal lymphocytes. Gut (1999) 0.92
Certolizumab pegol for the treatment of Crohn's disease. Therap Adv Gastroenterol (2011) 0.91
IFN-γ and TNF-α-induced GBP-1 inhibits epithelial cell proliferation through suppression of β-catenin/TCF signaling. Mucosal Immunol (2012) 0.90
Comparative tight junction protein expressions in colonic Crohn's disease, ulcerative colitis, and tuberculosis: a new perspective. Virchows Arch (2012) 0.90
Network dynamics determine the autocrine and paracrine signaling functions of TNF. Genes Dev (2014) 0.90
The JAK2 variant rs10758669 in Crohn's disease: altering the intestinal barrier as one mechanism of action. Int J Colorectal Dis (2011) 0.90
Gut Bacterial DNA Translocation is an Independent Risk Factor of Flare at Short Term in Patients With Crohn's Disease. Am J Gastroenterol (2016) 0.90
Potential role of superantigen induced activation of cell mediated immune mechanisms in the pathogenesis of Crohn's disease. Gut (1995) 0.90
Ankylosing spondylitis: introductory comments on its diagnosis and treatment. Ann Rheum Dis (2002) 0.90
The role of interferon alpha/beta in the induction of intestinal pathology in mice. Immunology (1991) 0.88
Tumor necrosis factor alpha blocking agents as treatment for ulcerative colitis intolerant or refractory to conventional medical therapy: a meta-analysis. PLoS One (2014) 0.87
The role of the tumor necrosis factor receptor in 2,4,6-trinitrobenzene sulfonic acid (TNBS)-induced colitis in mice. Dig Dis Sci (2005) 0.87
TNF transactivation of EGFR stimulates cytoprotective COX-2 expression in gastrointestinal epithelial cells. Am J Physiol Gastrointest Liver Physiol (2011) 0.87
A role for IL-4 in immunologically mediated enteropathy. Clin Exp Immunol (1995) 0.87
Thalidomide induces mucosal healing in Crohn's disease: case report. World J Gastroenterol (2011) 0.86
Cytokine production by intestinal intraepithelial lymphocyte subsets in celiac disease. Dig Dis Sci (2005) 0.85
Disruption of inflammatory signals by cytokine-targeted therapies for inflammatory bowel diseases. Br J Pharmacol (2012) 0.85
Tumour necrosis factor-alpha converting enzyme (TACE) activity in human colonic epithelial cells. Clin Exp Immunol (2004) 0.84
Tumour necrosis factor-alpha (TNF-alpha) transcription and translation in the CD4+ T cell-transplanted scid mouse model of colitis. Clin Exp Immunol (1999) 0.84
Differences in immunophenotyping of mucosal lymphocytes between ulcerative colitis and Crohn's disease. Korean J Intern Med (1997) 0.83
Prescribing patterns and awareness of adverse effects of infliximab: a health survey of gastroenterologists. Dig Dis Sci (2007) 0.81
Molecular aspects of tight junction barrier function. Curr Opin Pharmacol (2014) 0.81
Infliximab in ulcerative colitis. Biologics (2008) 0.80
From historical perspectives to modern therapy: a review of current and future biological treatments for Crohn's disease. Therap Adv Gastroenterol (2015) 0.80
Natural killer cells and tumour necrosis factor-alpha-mediated enteropathy in mice. Immunology (1993) 0.80
Portal vein thrombosis in a complicated case of Crohn's disease. Postgrad Med J (1992) 0.80
Orally administered RDP58 reduces the severity of dextran sodium sulphate induced colitis. Ann Rheum Dis (2002) 0.80
How bacteria-induced apoptosis of intestinal epithelial cells contributes to mucosal inflammation. Int J Inflam (2010) 0.79
KSR1 protects from interleukin-10 deficiency-induced colitis in mice by suppressing T-lymphocyte interferon-γ production. Gastroenterology (2010) 0.79
Diminished cytokine signalling against bacterial components in mononuclear leucocytes from ulcerative colitis patients after leukocytapheresis. Clin Exp Immunol (2005) 0.79
Juvenile onset spondyloarthropathies: therapeutic aspects. Ann Rheum Dis (2002) 0.78
Toll-like receptor-induced granulocyte-macrophage colony-stimulating factor secretion is impaired in Crohn's disease by nucleotide oligomerization domain 2-dependent and -independent pathways. Clin Exp Immunol (2008) 0.78
The distribution of immunoreactive interferon-gamma-containing cells in normal human tissues. Immunology (1992) 0.78
Effects of the gastrin-releasing peptide antagonist RC-3095 in a rat model of ulcerative colitis. Dig Dis Sci (2009) 0.78
Deficiency of Nuclear Receptor Nur77 Aggravates Mouse Experimental Colitis by Increased NFκB Activity in Macrophages. PLoS One (2015) 0.78
Nicotine enemas for active Crohn's colitis: an open pilot study. Gastroenterol Res Pract (2008) 0.77
Interleukin 2 and interferon-gamma augment anticolon antibody dependent cellular cytotoxicity in ulcerative colitis. Gut (1993) 0.77
Molecular mechanism of action of anti-tumor necrosis factor antibodies in inflammatory bowel diseases. World J Gastroenterol (2016) 0.76
Interferon-alpha (IFN-alpha) production by human intestinal mononuclear cells. Response to virus in control subjects and in Crohn's disease. Gut (1992) 0.76
Cytokine profiles in peripheral blood of children and adults with Crohn disease. J Pediatr Gastroenterol Nutr (2012) 0.76
Activation of nuclear factor kappaB as a target for anti-inflammatory therapy. Gut (1999) 0.76
Evaluation of Infliximab Effects on Gastrointestinal Bleeding in Crohn's Disease Using Double-Balloon Endoscopy. Case Rep Gastroenterol (2009) 0.75
Morinda citrifolia (Noni) Fruit Juice Reduces Inflammatory Cytokines Expression and Contributes to the Maintenance of Intestinal Mucosal Integrity in DSS Experimental Colitis. Mediators Inflamm (2017) 0.75
Serum Cytokine Profiles in Children with Crohn's Disease. Mediators Inflamm (2016) 0.75
Tumour necrosis factor-alpha decreases expression of the intestinal IgG Fc binding site by HT29-N2 cells. Immunology (1991) 0.75
Serum immune-activation potency and response to anti-TNF-α therapy in Crohn's disease. World J Gastroenterol (2010) 0.75
Crohn's disease (regional enteritis) of the large intestine and its distinction from ulcerative colitis. Gut (1960) 12.55
Cachectin: more than a tumor necrosis factor. N Engl J Med (1987) 8.74
Enhanced production of interleukin 1-beta by mononuclear cells isolated from mucosa with active ulcerative colitis of Crohn's disease. Gut (1989) 4.59
Independent regulation of tumor necrosis factor and lymphotoxin production by human peripheral blood lymphocytes. J Exp Med (1987) 4.54
Tumors secreting human TNF/cachectin induce cachexia in mice. Cell (1987) 4.19
Cachectin/tumor necrosis factor induces cachexia, anemia, and inflammation. J Exp Med (1988) 4.02
Tumor necrosis factor type alpha, a potent inhibitor of endothelial cell growth in vitro, is angiogenic in vivo. Proc Natl Acad Sci U S A (1987) 3.88
The role of cachectin/TNF in endotoxic shock and cachexia. Immunol Today (1988) 3.40
Expression of HLA-DR antigens by colonic epithelium in inflammatory bowel disease. Clin Exp Immunol (1983) 3.21
Intestinal lymphocyte subpopulations in inflammatory bowel disease: an analysis by immunohistological and cell isolation techniques. Gut (1984) 2.74
Crohn's disease in childhood. Arch Dis Child (1977) 2.50
Heterogeneity of HLA-DR-positive histiocytes in human intestinal lamina propria: a combined histochemical and immunohistological analysis. J Clin Pathol (1983) 2.49
The pathology of regional enteritis. Mil Surg (1951) 2.46
Macrophage subpopulations in lamina propria of normal and inflamed colon and terminal ileum. Gut (1989) 2.44
Bowel necrosis induced by tumor necrosis factor in rats is mediated by platelet-activating factor. J Clin Invest (1988) 2.23
Tumor necrosis factor and endotoxin induce similar metabolic responses in human beings. Surgery (1988) 1.98
Interleukin 2 receptor expression by macrophages in inflammatory bowel disease. Clin Exp Immunol (1988) 1.95
Methane excretion in man--a study of breath, flatus, and faeces. Gut (1985) 1.88
In vivo profiles of eicosanoids in ulcerative colitis, Crohn's colitis, and Clostridium difficile colitis. Gastroenterology (1988) 1.86
Macrophage heterogeneity in normal colonic mucosa and in inflammatory bowel disease. Gut (1988) 1.67
Prostanoid synthesis by cultured intestinal epithelial and mononuclear cells in inflammatory bowel disease. Gut (1983) 1.42
Altered patterns of secretion of monomeric IgA and IgA subclass 1 by intestinal mononuclear cells in inflammatory bowel disease. Gastroenterology (1986) 1.31
Dendritic cells and scavenger macrophages in chronic inflammatory bowel disease. Gut (1989) 1.29
Immunoregulatory function of lamina propria T cells in Crohn's disease. Gastroenterology (1985) 1.27
HLA-DR expression in human fetal intestinal epithelium. Gut (1988) 1.23
T cell-B cell regulation in the intestinal lamina propria in Crohn's disease. Gastroenterology (1985) 1.21
Expression of HLA-DR antigens in inflammatory bowel disease mucosa: role of intestinal lamina propria mononuclear cell-derived interferon gamma. Dig Dis Sci (1988) 1.13
Differential secretion of tumor necrosis factor-alpha and granulocyte/macrophage colony-stimulating factors but not interferon-gamma from CD4+ compared to CD8+ human T cell clones. Eur J Immunol (1989) 1.08
The detection and enumeration of cytokine-secreting cells in mice and man and the clinical application of these assays. J Immunol Methods (1989) 1.03
The flow of oxygen through the pulmonary epithelium. J Physiol (1920) 9.27
Prevention of insulin-dependent diabetes mellitus in non-obese diabetic mice by transgenes encoding modified I-A beta-chain or normal I-E alpha-chain. Nature (1990) 2.23
Selective decontamination of the digestive tract reduces gram-negative pulmonary colonization but not systemic endotoxemia in patients undergoing elective liver transplantation. Crit Care Med (1994) 2.21
Transfer of diabetes in mice prevented by blockade of adhesion-promoting receptor on macrophages. Nature (1990) 2.10
Suppressor T cells in experimental autoimmune haemolytic anaemia. Nature (1978) 1.79
Infection with Schistosoma mansoni prevents insulin dependent diabetes mellitus in non-obese diabetic mice. Parasite Immunol (1999) 1.71
ENCORE: the effect of nutrient enrichment on coral reefs. Synthesis of results and conclusions. Mar Pollut Bull (2001) 1.69
Parasitic worms and inflammatory diseases. Parasite Immunol (2006) 1.58
Biochemical assessment of protein-calorie malnutrition. Lancet (1969) 1.55
Characterization of pancreatic islet cell infiltrates in NOD mice: effect of cell transfer and transgene expression. Eur J Immunol (1991) 1.41
Autoreactive T-cell lines specific for mouse thyroglobulin. Immunology (1985) 1.41
Variable transfer of Y-specific sequences in XX males. Nucleic Acids Res (1986) 1.40
The Prader-Willi syndrome. Arch Dis Child (1994) 1.39
In vivo activity and in vitro specificity of CD4+ Th1 and Th2 cells derived from the spleens of diabetic NOD mice. J Clin Invest (1995) 1.36
Idiotypic networks and their possible exploitation for manipulation of the immune response. Lancet (1981) 1.29
Red cell volume and cardiac output in anaemic preterm infants. Arch Dis Child (1990) 1.22
Identification of a thyroxine-containing self-epitope of thyroglobulin which triggers thyroid autoreactive T cells. J Exp Med (1991) 1.20
The transfer of autoimmune diabetes in NOD mice can be inhibited or accelerated by distinct cell populations present in normal splenocytes taken from young males. J Autoimmun (1990) 1.19
Mapping the testis determinants by an analysis of Y-specific sequences in males with apparent XX and XO karyotypes and females with XY karyotypes. Nucleic Acids Res (1987) 1.18
Autoimmunity and idiotypes. Lancet (1984) 1.17
Duchenne muscular dystrophy due to familial Xp21 deletion detectable by DNA analysis and flow cytometry. Hum Genet (1986) 1.16
Specific monoclonal IgM is a potent adjuvant in murine malaria vaccination. Nature (1983) 1.15
Mycobacteria precipitate an SLE-like syndrome in diabetes-prone NOD mice. Immunology (1994) 1.15
Biotin labeling of red cells in the measurement of red cell volume in preterm infants. Pediatr Res (1990) 1.15
Complement lytic activity has no role in the pathogenesis of autoimmune diabetes in NOD mice. Diabetes (1993) 1.15
Outbreak of SRSV gastroenteritis at an international conference traced to food handled by a post-symptomatic caterer. Epidemiol Infect (1993) 1.14
Cutting edge: interactions through the IL-10 receptor regulate autoimmune diabetes. J Immunol (2001) 1.13
Immunoglobulins, transferrin, caeruloplasmin and heterophile antibodies in kwashiorkor. Trop Geogr Med (1970) 1.12
Mutator transposase is widespread in the grasses. Plant Physiol (2001) 1.10
Genotype-phenotype correlations in XX males and their bearing on current theories of sex determination. Hum Genet (1990) 1.10
Ornithine decarboxylase in phytohaemagglutinin stimulated lymphocytes: Control of degradation rate by amino acids. FEBS Lett (1972) 1.09
A thyroxine-containing peptide can induce murine experimental autoimmune thyroiditis. J Exp Med (1992) 1.09
Distinct macrophage subpopulations in pancreas of prediabetic BB/E rats. Possible role for macrophages in pathogenesis of IDDM. Diabetes (1988) 1.09
Connective tissue abnormalities in MRL/1 mice. Ann Rheum Dis (1986) 1.08
Improvement in quality of life of children with acute Crohn's disease does not parallel mucosal healing after treatment with exclusive enteral nutrition. Aliment Pharmacol Ther (2004) 1.07
A distinct subset of chemokines dominates the mucosal chemokine response in inflammatory bowel disease. Aliment Pharmacol Ther (2005) 1.06
Interleukin-13 prevents autoimmune diabetes in NOD mice. Diabetes (1999) 1.06
Phenotypic characteristics of cells involved in induced suppression to murine experimental autoimmune thyroiditis. Eur J Immunol (1988) 1.05
Analysis of the cellular interactions involved in the regulation of induced erythrocyte autoantibodies. Cell Immunol (1981) 1.05
Th17-cell plasticity in Helicobacter hepaticus-induced intestinal inflammation. Mucosal Immunol (2013) 1.04
A novel acropectoral syndrome maps to chromosome 7q36. J Med Genet (2001) 1.04
The detection and enumeration of cytokine-secreting cells in mice and man and the clinical application of these assays. J Immunol Methods (1989) 1.03
Increased expression of laminin/collagen receptor (VLA-1) on epithelium of inflamed human intestine. J Clin Pathol (1990) 1.02
High efficiency antigen presentation by thyroglobulin-primed murine splenic B cells. Eur J Immunol (1987) 1.02
alpha-Cell neogenesis in an animal model of IDDM. Diabetes (1997) 1.02
Pre-diabetes in the spontaneously diabetic BB/E rat: lymphocyte subpopulations in the pancreatic infiltrate and expression of rat MHC class II molecules in endocrine cells. Diabetologia (1985) 1.02
Hyper-responsiveness in NZB mice to the experimental induction of anti-red cell autoantibody. Clin Exp Immunol (1977) 1.02
Specific and non-specific suppressor cell activity in NZB mice. Immunology (1980) 1.02
Independent segregation of NZB immune abnormalities in NZB x C58 recombinant inbred mice. Eur J Immunol (1982) 1.02
Duodenal iron proteins in idiopathic hemochromatosis. J Clin Invest (1989) 1.01
The involvement of Ly2+ T cells in beta cell destruction. J Autoimmun (1990) 1.01
Effect of aldehyde cross-linking on human dermal collagen implants in the rat. Br J Exp Pathol (1980) 1.00
Adjuvant composition determines the induction of type II collagen-induced arthritis. Scand J Immunol (1992) 0.99
Altered course of visceral leishmaniasis in mice expressing transgenic I-E molecules. Eur J Immunol (1992) 0.99
The use of a non-depleting anti-CD4 monoclonal antibody to re-establish tolerance to beta cells in NOD mice. Eur J Immunol (1992) 0.99
How is the source of food poisoning outbreaks established? The example of three consecutive Salmonella enteritidis PT4 outbreaks linked to eggs. J Epidemiol Community Health (1991) 0.98
Idiotypes and autoimmunity. Springer Semin Immunopathol (1983) 0.98
Parents' experiences and expectations of care in pregnancy after stillbirth or neonatal death: a metasynthesis. BJOG (2014) 0.98
Grammatical and resource components of sentence processing in Parkinson's disease: an fMRI study. Neurology (2003) 0.97
Immunological defects in SJL mice. Immunology (1986) 0.97
Standards for ovarian volume in childhood and puberty. Fertil Steril (1993) 0.96
Glycosylation of IgG, immune complexes and IgG subclasses in the MRL-lpr/lpr mouse model of rheumatoid arthritis. Eur J Immunol (1990) 0.96
Deficient production of anti-red cell autoantibodies by mice with an X-linked B lymphocyte defect. Eur J Immunol (1979) 0.96
Anorexia nervosa complicating inflammatory bowel disease. Arch Dis Child (1990) 0.96
Defective regulation of erythrocyte autoantibodies in SJL mice. Immunology (1984) 0.96
Histopathology and immunohistochemistry of the caecum in children with the Trichuris dysentery syndrome. J Clin Pathol (1991) 0.96
Erythrocyte nucleoside and sugar transport. Endo-beta-galactosidase and endoglycosidase-F digestion of partially purified human and pig transporter proteins. Biochem J (1986) 0.95
Suppression of induced erythrocyte autoantibodies is dependent on Lyt 1 cells. Immunology (1985) 0.95
Reduced heparan sulfate accumulation in enterocytes contributes to protein-losing enteropathy in a congenital disorder of glycosylation. Am J Pathol (2000) 0.95
Inflammatory bowel disease associated with immune thrombocytopenic purpura in children. J Pediatr Gastroenterol Nutr (2001) 0.95
Methylene tetrahydrofolate reductase (MTHFR) and nitric oxide synthase (ecNOS) genes and risks of peripheral arterial disease and coronary heart disease: Edinburgh Artery Study. Atherosclerosis (2000) 0.94
Both CD4(+) T cells and CD8(+) T cells are required for iodine accelerated thyroiditis in NOD mice. Cell Immunol (1999) 0.94
Diagnosis in Prader-Willi syndrome. Arch Dis Child (1994) 0.94
Lack of autoantigen-specific splenic suppressor cells in mice with an X-linked B-lymphocyte defect. Immunology (1980) 0.94
Early interactions of Salmonella enterica serovar typhimurium with human small intestinal epithelial explants. Gut (2004) 0.94
Antibody mediated regulation of immune responses. I. Enhancement of specific antibody responses through IgM antibodies. Immunol Lett (1982) 0.93
Complete characterization of the expressed immune response genes in Biozzi AB/H mice: structural and functional identity between AB/H and NOD A region molecules. Immunogenetics (1993) 0.93
Absence of learning difficulties in a hyperactive boy with a terminal Xp deletion encompassing the MRX49 locus. J Med Genet (2001) 0.91
Cytotoxicity of tumor necrosis factor for thyroid epithelial cells and its regulation by interferon-gamma. Eur J Immunol (1987) 0.91
II. IgM-mediated enhancement: dependency on antigen dose, T-cell requirement and lack of evidence for an idiotype-related mechanism. Immunology (1983) 0.91
Cyclosporine affects the function of antigen-presenting cells. Immunology (1986) 0.91
Gastric carcinoid: germline and somatic mutation of the neurofibromatosis type 1 gene. Fam Cancer (2007) 0.90
Interferon-mediated enhancement of thyroid major histocompatibility complex antigen expression. A flow cytometric analysis. Scand J Immunol (1987) 0.90
Tissue tropism of enteropathogenic Escherichia coli strains belonging to the O55 serogroup. Infect Immun (2002) 0.90
Myeloperoxidase autoantibodies distinguish vasculitis mediated by anti-neutrophil cytoplasm antibodies from immune complex disease in MRL/Mp-lpr/lpr mice: a spontaneous model for human microscopic angiitis. Eur J Immunol (1998) 0.90
Triggering a second T cell receptor on diabetogenic T cells can prevent induction of diabetes. J Exp Med (1999) 0.90
Is there restricted T cell receptor usage in autoimmune disease? Clin Exp Immunol (1991) 0.89
Helper and suppressor activities of an autoreactive mouse thyroglobulin-specific T-cell clone. Immunology (1986) 0.89
The effect of bone marrow and thymus chimerism between non-obese diabetic (NOD) and NOD-E transgenic mice, on the expression and prevention of diabetes. Eur J Immunol (1993) 0.89
Familial Wolf-Hirschhorn syndrome resulting from a cryptic translocation: a clinical and molecular study. J Med Genet (1996) 0.88
Activated eosinophils in chronic inflammatory bowel disease. Lancet (1990) 0.88